Cargando…

Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study

As an emerging hotspot for patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC), neoadjuvant immunochemotherapy (nICT) is safe and feasible. Pathological complete response (pCR) is considered to be an important therapeutic effect of neoadjuvant therapy. However, few studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Jifeng, Wang, Liang, Yang, Xun, Chen, Qixun, Cheng, Xiangdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901900/
https://www.ncbi.nlm.nih.gov/pubmed/35880397
http://dx.doi.org/10.17305/bjbms.2022.7696
_version_ 1784883122977898496
author Feng, Jifeng
Wang, Liang
Yang, Xun
Chen, Qixun
Cheng, Xiangdong
author_facet Feng, Jifeng
Wang, Liang
Yang, Xun
Chen, Qixun
Cheng, Xiangdong
author_sort Feng, Jifeng
collection PubMed
description As an emerging hotspot for patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC), neoadjuvant immunochemotherapy (nICT) is safe and feasible. Pathological complete response (pCR) is considered to be an important therapeutic effect of neoadjuvant therapy. However, few studies have explored pCR predictors for nICT in LA-ESCC. The purpose of this study was to predict pCR after nICT in LA-ESCC by pretreatment clinical characteristics and hematological indexes. The primary endpoint was to explore the impacts on the predictors for pCR prediction. Clinical characteristics and hematological indexes, including systemic immune-inflammation index (SII), neutrophil lymphocyte ratio (NLR), lymphocyte monocyte ratio (LMR), prognostic nutritional index (PNI), and platelet lymphocyte ratio (PLR), were conducted. A total of 150 LA-ESCC patients were enrolled in the current study. There were 14 (9.3%) female and 136 (90.7%) male patients. Fifty-two patients achieved pCR (34.7%). A higher pCR rate was found in low-NLR group (43.7% vs. 26.6%, P = 0.028) and high-LMR group (43.8% vs. 21.3%, P = 0.004), respectively. Differentiation [odds ratio (OR) = 0.464, 95% confidence interval (CI) = 0.259–0.830, P = 0.010], LMR (OR = 0.309, 95% CI = 0.132–0.707, P = 0.007), and clinical TNM (cTNM) (OR = 0.225, 95% CI = 0.115–0.441, P < 0.001) were the independent predictors for pCR. The nomogram for pCR prediction based on LMR, differentiation, and cTNM stage had good discrimination performance and calibration coordination (C-index = 0.779). The results of our study are of great significance for designing therapeutic strategies. Nomogram based on LMR, differentiation, and cTNM may accurately and effectively predict pCR.
format Online
Article
Text
id pubmed-9901900
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
record_format MEDLINE/PubMed
spelling pubmed-99019002023-02-07 Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study Feng, Jifeng Wang, Liang Yang, Xun Chen, Qixun Cheng, Xiangdong Biomol Biomed Research Article As an emerging hotspot for patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC), neoadjuvant immunochemotherapy (nICT) is safe and feasible. Pathological complete response (pCR) is considered to be an important therapeutic effect of neoadjuvant therapy. However, few studies have explored pCR predictors for nICT in LA-ESCC. The purpose of this study was to predict pCR after nICT in LA-ESCC by pretreatment clinical characteristics and hematological indexes. The primary endpoint was to explore the impacts on the predictors for pCR prediction. Clinical characteristics and hematological indexes, including systemic immune-inflammation index (SII), neutrophil lymphocyte ratio (NLR), lymphocyte monocyte ratio (LMR), prognostic nutritional index (PNI), and platelet lymphocyte ratio (PLR), were conducted. A total of 150 LA-ESCC patients were enrolled in the current study. There were 14 (9.3%) female and 136 (90.7%) male patients. Fifty-two patients achieved pCR (34.7%). A higher pCR rate was found in low-NLR group (43.7% vs. 26.6%, P = 0.028) and high-LMR group (43.8% vs. 21.3%, P = 0.004), respectively. Differentiation [odds ratio (OR) = 0.464, 95% confidence interval (CI) = 0.259–0.830, P = 0.010], LMR (OR = 0.309, 95% CI = 0.132–0.707, P = 0.007), and clinical TNM (cTNM) (OR = 0.225, 95% CI = 0.115–0.441, P < 0.001) were the independent predictors for pCR. The nomogram for pCR prediction based on LMR, differentiation, and cTNM stage had good discrimination performance and calibration coordination (C-index = 0.779). The results of our study are of great significance for designing therapeutic strategies. Nomogram based on LMR, differentiation, and cTNM may accurately and effectively predict pCR. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023-02-01 2023-01-06 /pmc/articles/PMC9901900/ /pubmed/35880397 http://dx.doi.org/10.17305/bjbms.2022.7696 Text en © 2022 Feng et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Feng, Jifeng
Wang, Liang
Yang, Xun
Chen, Qixun
Cheng, Xiangdong
Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study
title Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study
title_full Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study
title_fullStr Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study
title_full_unstemmed Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study
title_short Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study
title_sort prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: a real-world study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901900/
https://www.ncbi.nlm.nih.gov/pubmed/35880397
http://dx.doi.org/10.17305/bjbms.2022.7696
work_keys_str_mv AT fengjifeng predictionofpathologiccompleteresponsepredictioninpatientswithlocallyadvancedesophagealsquamouscellcarcinomatreatedwithneoadjuvantimmunochemotherapyarealworldstudy
AT wangliang predictionofpathologiccompleteresponsepredictioninpatientswithlocallyadvancedesophagealsquamouscellcarcinomatreatedwithneoadjuvantimmunochemotherapyarealworldstudy
AT yangxun predictionofpathologiccompleteresponsepredictioninpatientswithlocallyadvancedesophagealsquamouscellcarcinomatreatedwithneoadjuvantimmunochemotherapyarealworldstudy
AT chenqixun predictionofpathologiccompleteresponsepredictioninpatientswithlocallyadvancedesophagealsquamouscellcarcinomatreatedwithneoadjuvantimmunochemotherapyarealworldstudy
AT chengxiangdong predictionofpathologiccompleteresponsepredictioninpatientswithlocallyadvancedesophagealsquamouscellcarcinomatreatedwithneoadjuvantimmunochemotherapyarealworldstudy